Compare Cognizant Technology Solutions Corp (CTSH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Novartis AG — how do they compare? Cognizant Technology Solutions Corp trades at $60.12 (market cap $25.71B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 10.7× Cognizant Technology Solutions Corp's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Novartis AG for 82 Days on average.
| CTSH | NVS | |
|---|---|---|
Market Cap | $25.71B | $274.00B |
Volume | 5,152,376 | 1,852,137 |
Sector | Technology | Health |
52-Week High | $86.70 | $168.62 |
52-Week Low | $38.73 | $121.80 |
Typical Hold Time | 57 Days | 82 Days |
Enterprise Value | $26.75B | $315.32B |
Dividend Yield | 2.31% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $60.01, up 4.88% on the day, with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with a P/E of 12.25 and net income margin of 10.26%, while revenue grew to $21.11B in 2025. Analyst consensus is mixed with a $64.25 price target, and the company continues to gain recognition for AI-driven initiatives and workplace excellence.
CTSH presents a balanced outlook with undervalued metrics and strong cash flow, but faces headwinds from technical bearishness and competitive IT spending pressures. The upcoming Q3 2026 earnings on October 29, 2026, will be critical for confirming growth trajectory amid evolving AI integration strategies.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
